Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO2P5G
|
|||
| Drug Name |
CVN058
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 1 | [1] | |
| Company |
Cerevance
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 3 receptor (5HT3R) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03669250) CVN058 Effect on Mismatch Negativity in Schizophrenics. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Cerevance. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.